Website
News25/Ratings11
News · 26 weeks55+200%
2025-10-262026-04-19
Mix2690d
- Insider9(35%)
- Other6(23%)
- SEC Filings6(23%)
- Earnings4(15%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form DEFA14A filed by SI-BONE Inc.DEFA14A - SI-BONE, Inc. (0001459839) (Filer)
- SECSEC Form DEF 14A filed by SI-BONE Inc.DEF 14A - SI-BONE, Inc. (0001459839) (Filer)
- PRSI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/vde24u4q. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast
- INSIDERSEC Form 4 filed by Hinckley Greg K4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSEC Form 4 filed by Maheshwari Anshul4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSEC Form 4 filed by Pisetsky Michael A.4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)
- INSIDERDirector Nishimura Mika sold $56,700 worth of shares (4,100 units at $13.83), decreasing direct ownership by 11% to 32,716 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECSEC Form S-8 filed by SI-BONE Inc.S-8 - SI-BONE, Inc. (0001459839) (Filer)
- SECSEC Form S-3ASR filed by SI-BONE Inc.S-3ASR - SI-BONE, Inc. (0001459839) (Filer)
- SECSEC Form 10-K filed by SI-BONE Inc.10-K - SI-BONE, Inc. (0001459839) (Filer)
- PRSmith+Nephew signs distribution agreement with SI-BONETrauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures."We're incredibly excited to partner with SI-BONE," said Scott Gunn, Vice President Trauma, Extremities and Shoulder. "This collaboration reflects a share
- SECSI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - SI-BONE, Inc. (0001459839) (Filer)
- PRSI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 GuidanceAchieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.3 million, representing growth of 15.0%U.S. revenue of $53.5 million, representing growth of 13.9%Gross margin of 79.0%Net loss of $1.6 million, r
- INSIDERRecupero Anthony J sold $324,204 worth of shares (21,049 units at $15.40), decreasing direct ownership by 8% to 243,418 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. was granted 78,294 shares and sold $318,642 worth of shares (20,756 units at $15.35), increasing direct ownership by 25% to 285,974 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERChief Executive Officer Francis Laura was granted 229,481 shares and sold $1,432,122 worth of shares (93,475 units at $15.32), increasing direct ownership by 33% to 544,369 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERChief Financial Officer Maheshwari Anshul was granted 107,992 shares and sold $330,982 worth of shares (21,528 units at $15.37), increasing direct ownership by 48% to 266,466 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)
- PRSI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/hkU3gw9TuYE3fDbRaRPY9r. Live audio of the webcast will be available on the "Investors" sect
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SI-BONE Inc.SCHEDULE 13G/A - SI-BONE, Inc. (0001459839) (Subject)
- SECSEC Form SCHEDULE 13G filed by SI-BONE Inc.SCHEDULE 13G - SI-BONE, Inc. (0001459839) (Subject)
- INSIDERDirector Dunn Jeffrey W sold $5,532 worth of shares (337 units at $16.42), decreasing direct ownership by 3% to 9,970 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- PRSI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the "Investors" section of the company's websi